Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
6.02
-0.83 (-12.12%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Company Description

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo.

Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Forte Biosciences, Inc.
Forte Biosciences logo
Country United States
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Paul A. Wagner

Contact Details

Address:
3060 Pegasus Park Drive, Building 6
Dallas, Texas 75247
United States
Phone 310 618 6994
Website fortebiorx.com

Stock Details

Ticker Symbol FBRX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001419041
CUSIP Number 34962G109
ISIN Number US34962G1094
Employer ID 26-1243872
SIC Code 2834

Key Executives

Name Position
Dr. Paul A. Wagner Ph.D. Chief Executive Officer, President and Chairman
Antony A. Riley CPA Chief Financial Officer
Dr. Barbara K. Finck M.D. Chief Medical Clinician and Director
Christopher Roenfeldt Chief Operating Officer

Latest SEC Filings

Date Type Title
Apr 18, 2025 8-K Current Report
Apr 4, 2025 8-K Current Report
Apr 3, 2025 EFFECT Notice of Effectiveness
Mar 28, 2025 S-3 Registration statement under Securities Act of 1933
Mar 28, 2025 10-K Annual Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 SCHEDULE 13G/A Filing